Edition:
United States

Supernus Pharmaceuticals Inc (SUPN.O)

SUPN.O on Consolidated Issue listed on NASDAQ Global Market

43.20USD
18 Aug 2017
Change (% chg)

$-0.30 (-0.69%)
Prev Close
$43.50
Open
$43.30
Day's High
$43.85
Day's Low
$42.81
Volume
626,131
Avg. Vol
607,534
52-wk High
$46.45
52-wk Low
$17.25

SUPN.O

Chart for SUPN.O

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $2,190.20
Shares Outstanding(Mil.): 50.70
Dividend: --
Yield (%): --

Financials

  SUPN.O Industry Sector
P/E (TTM): 21.71 31.45 32.56
EPS (TTM): 1.99 -- --
ROI: 50.40 15.33 14.89
ROE: 61.13 16.35 16.13

BRIEF-Supernus defeats second generic challenger to Oxtellar XR

* Supernus - Court ruled TWi Pharmaceuticals, unit infringed U.S. Patents by submitting to FDA, ANDA to market generic version of Oxtellar XR Source text for Eikon: Further company coverage:

Aug 15 2017

BRIEF-Supernus Q2 earnings per share $0.32

* Supernus announces record second quarter 2017 financial results

Aug 02 2017

BRIEF-Supernus says Shire receives FDA approval for Mydayis for ADHD

* Supernus announces that its partner Shire receives FDA approval for Mydayis™ for ADHD

Jun 21 2017

BRIEF-Supernus announces Q1 earnings per share $0.19

* Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S

May 09 2017

BRIEF-Supernus receives final FDA approval for trokendi XR

* Supernus receives final FDA approval for trokendi XR for migraine prophylaxis in adults and adolescents

Apr 05 2017

BRIEF-Supernus announces settlement with Actavis on Trokendi XR patent litigation

* Supernus announces settlement with Actavis on Trokendi XR patent litigation

Mar 07 2017

BRIEF-Cadila Healthcare says Zydus announces settlement with Supernus on Trokendi XR extended-release capsules

* Says Zydus announces settlement with Supernus on Trokendi XR® (Topiramate) extended-release capsules

Mar 07 2017

BRIEF-Supernus announces settlement with Zydus on Trokendi XR patent litigation

* Supernus announces settlement with Zydus on Trokendi XR patent litigation

Mar 06 2017

BRIEF-Supernus Pharmaceuticals files for non-timely 10-K

* Supernus Pharmaceuticals Inc - files for non-timely 10-K Source text: (http://bit.ly/2ldW969) Further company coverage:

Mar 01 2017

BRIEF-Supernus Q4 earnings per share $0.26

* Supernus announces record fourth quarter and full year 2016 financial results

Feb 28 2017

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $48.74 -0.55
AstraZeneca plc (AZN.L) 4,447.00 -34.00
Eli Lilly and Co (LLY.N) $77.07 -0.73
Shire PLC (SHP.L) 3,764.50 -106.50
Shire PLC (3159084.L) -- --
Smiths Group plc (SMIN.L) 1,549.00 -13.00

Earnings vs. Estimates